Related references
Note: Only part of the references are listed.Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study
Samuel Dagogo-Jack et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Julio Rosenstock et al.
DIABETES OBESITY & METABOLISM (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Francesca Cinti et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone
Steven G. Terra et al.
DIABETES OBESITY & METABOLISM (2017)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2017 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2017)
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Sanjay Kalra et al.
ADVANCES IN THERAPY (2016)
Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes-2016 (vol 39, pg S13, 2016)
DIABETES CARE (2016)
SGLT2 Inhibitors and the Diabetic Kidney
Paola Fioretto et al.
DIABETES CARE (2016)
8. Pharmacologic Approaches to Glycemic Treatment
DIABETES CARE (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
Andrew Lewin et al.
DIABETES CARE (2015)
Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
N. B. Amin et al.
DIABETES OBESITY & METABOLISM (2015)
Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin
N. B. Amin et al.
DIABETES OBESITY & METABOLISM (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Pharmacologic Management of Type 2 Diabetes
William Harper et al.
CANADIAN JOURNAL OF DIABETES (2013)
Clinical Inertia in People With Type 2 Diabetes A retrospective cohort study of more than 80,000 people
Kamlesh Khunti et al.
DIABETES CARE (2013)
Achievement of Goals in U.S. Diabetes Care, 1999-2010
Mohammed K. Ali et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Executive Summary: Standards of Medical Care in Diabetes--2012
DIABETES CARE (2011)
Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy
A. Z. Fu et al.
DIABETES OBESITY & METABOLISM (2011)
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents
L. Olansky et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
Itamar Raz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials
Avraham Karasik et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Insulinogenic indices from insulin and C-peptide: Comparison of beta-cell function from OGTT and IVGTT
Andrea Tura et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2006)
Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
SE Inzucchi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Share Paper
